Get with the Guidelines

Edit Answers
12345678910111213
Across
  1. 3. Answer Direction Shaded Letter(s)
  2. 5. of MRAs like eplerenone that block the effects of a certain mineralocorticoid. ALDOSTERONE Down E (7th)
  3. 8. that must be monitored closely when starting ACEi or MRAs. POTASSIUM Across P, M (1st, 9th)
  4. 10. MRA known to cause gynecomastia due to non-selective steroid binding. SPIRONOLACTONE Across S, N, T (1st, 6th, 10th)
  5. 12. therapy class; carvedilol and bisoprolol are evidence-based examples. BETABLOCKER Across B, E (1st, 2nd)
  6. 13. first-line RAS inhibitor; a combination of sacubitril and valsartan. ARNI Across A (4th)
Down
  1. 1. the I(f) current in the SA node; used if HR >70 despite max beta-blockers. IVABRADINE Down A (3rd)
  2. 2. for self-identified Black patients with NYHA Class III-IV HF. HYDRALAZINE Down D (3rd)
  3. 4. for symptom relief of fluid overload; does not provide mortality benefit. LOOP Down O (2nd)
  4. 6. "C" in ACE-inhibitor; class including lisinopril and enalapril. CONVERTING Across C (1st)
  5. 7. HFrEF "Four Pillars" Crossword
  6. 9. class of "flozins" that reduces HF hospitalizations regardless of glycemic status. SGLT2I Down E (n/a*)
  7. 11. inotrope used for rate control in AFib or refractory symptoms. DIGOXIN Across O (4th)